BAP1 and Miyoshi myopathy: Thus, aspirin administration to individuals at high risk of developing MM, such as those with a history of asbestos and or erionite exposure or germline BAP1 mutation carriers,1, 2 may prevent or delay the growth of MM, possibly increasing life expectancy and also increasing opportunities for early MM detection, which is associated with a prolonged life expectancy.1 In this regard, promising new MM biomarkers are being developed to increase opportunities for early MM detection in cohorts at high risk for MM.3, 30